Core Viewpoint - HCW Biologics Inc. has received a notice from Nasdaq regarding its failure to meet the market value listing requirements, which may lead to delisting unless the company successfully appeals [1][5]. Company Overview - HCW Biologics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies aimed at extending healthspan by addressing chronic inflammation linked to age-related diseases, including cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, and long-haul COVID-19 [6]. Compliance and Delisting Notice - On June 20, 2024, HCW Biologics was notified that its market value of listed securities fell below the $50 million threshold for 30 consecutive business days, leading to a compliance period of 180 days, which ended on December 16, 2024 [1]. - The company did not regain compliance by the deadline, resulting in a notice of potential delisting from Nasdaq unless a hearing is requested [1][5]. Appeal Process - HCW Biologics intends to request a hearing before the Nasdaq Hearing Panel, which will pause any delisting actions while the appeal is considered [5]. - The Panel can grant an extension of up to 180 days for the company to demonstrate compliance with the listing criteria [5].
HCW Biologics Inc. Received NASDAQ Staff Determination Letter